Drug industry lawyers say the Federal Trade Commission’s stepped-up efforts through the courts and its own regulatory actions to stop drug makers from using device patents to block marketing of generic combination products could take some pressure off FDA to clarify its Orange Book stance. FTC officials recently put industry on notice it might go after more drug companies than the 10 inhaler makers it recently sent letters to, and on Monday (April 8) again repeated their calls for drug...